Definium Therapeutics, Inc. (DFTX)
36.26
+0.03
(+0.08%)
USD |
NASDAQ |
Oct 06, 09:44
Definium Therapeutics Enterprise Value : 3.821B for Oct. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 05, 2026 | 3.821B |
| October 02, 2026 | 3.978B |
| October 01, 2026 | 4.005B |
| September 30, 2026 | 4.067B |
| September 29, 2026 | 4.087B |
| September 28, 2026 | 4.114B |
| September 25, 2026 | 3.813B |
| September 24, 2026 | 3.888B |
| September 23, 2026 | 4.011B |
| September 22, 2026 | 4.370B |
| September 21, 2026 | 4.230B |
| September 18, 2026 | 4.167B |
| September 17, 2026 | 4.150B |
| September 16, 2026 | 4.038B |
| September 15, 2026 | 3.900B |
| September 14, 2026 | 4.361B |
| September 11, 2026 | 4.178B |
| September 10, 2026 | 4.022B |
| September 09, 2026 | 4.057B |
| September 08, 2026 | 4.089B |
| September 04, 2026 | 4.071B |
| September 03, 2026 | 4.058B |
| September 02, 2026 | 4.179B |
| September 01, 2026 | 4.126B |
| August 31, 2026 | 4.290B |
| Date | Value |
|---|---|
| August 28, 2026 | 4.459B |
| August 27, 2026 | 4.841B |
| August 26, 2026 | 4.834B |
| August 25, 2026 | 4.974B |
| August 24, 2026 | 4.767B |
| August 21, 2026 | 4.987B |
| August 20, 2026 | 5.053B |
| August 19, 2026 | 5.109B |
| August 18, 2026 | 5.158B |
| August 17, 2026 | 5.034B |
| August 14, 2026 | 4.681B |
| August 13, 2026 | 4.851B |
| August 12, 2026 | 4.702B |
| August 11, 2026 | 4.450B |
| August 10, 2026 | 5.019B |
| August 07, 2026 | 5.152B |
| August 06, 2026 | 5.152B |
| August 05, 2026 | 4.917B |
| August 04, 2026 | 4.639B |
| August 03, 2026 | 4.568B |
| July 31, 2026 | 4.800B |
| July 30, 2026 | 4.931B |
| July 29, 2026 | 4.617B |
| July 28, 2026 | 4.591B |
| July 27, 2026 | 4.683B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Enliven Therapeutics, Inc. | 2.437B |
| Cocrystal Pharma, Inc. | 14.40M |
| CNBX Pharmaceuticals, Inc. | 1.305M |
| Arvinas, Inc. | -72.56M |
| Fulcrum Therapeutics, Inc. | -30.54M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -158.99M |
| Total Expenses (Quarterly) | 158.99M |
| EPS Diluted (Quarterly) | -1.436 |
| Earnings Yield | -9.48% |
| Normalized Earnings Yield | -7.018 |